Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Novavax

Vaxart

They each have a key competitive edge that could set them apart.

3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic World

Pfizer

The first to market won't necessarily dominate the market over the long run.

These 2 Early-Stage COVID Vaccines Could Be Game-Changers

BioNTech SE

Johnson & Johnson

Moderna

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

COVID Vaccine Stock Ideas for Different Investors

There's something for every kind of investor with this list.

3 Top Coronavirus Stocks to Buy in December

This could be the perfect time for aggressive investors to scoop up shares.

Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now

iBio

Marinus Pharmaceuticals

This can happen when a company holds out its hand for a big chunk of fresh capital.

Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Pricing of $150.15 Million Public Offering of Common Stock

 Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject t

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

Don't be surprised if this small biotech takes off in 2021.

Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch

CureVac B.V

Telesis Bio Inc

Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.

3 mRNA Coronavirus Vaccine Stocks to Check Out That Aren't Pfizer, BioNTech, or Moderna

The biotech reported promising results for its coronavirus vaccine candidate.

Why Arcturus Therapeutics Stock Soared Today

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2020 Results - Quick Version Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Interim ARCT-021 Phase 1/2 Study Results, and Up to $220 Million in Additional Financial Commitments from Singapore

Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

It's still really early for these two biotech stocks. But their experimental COVID-19 vaccines have tremendous potential.

2 Under-the-Radar Coronavirus Vaccine Stocks to Watch

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcturus Therapeutics (ARCT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for OTC Deficiency

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against  SARS-CoV-2 infection following a single vaccination

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

Based on excitement over its Covid-19 vaccine candidate, LUNAR-COV19 (also known as ARCT-021,) Arcturus today sports a market capitalization of an even $1 billion.

Key Takeaways From Arcturus Therapeutics’ Management Presentation Today

Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Arcturus Therapeutics (ARCT) Stock?

SAN DIEGO, Aug.  18, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply COVID-19 STARR™ mRNA vaccine candidate (ARCT-021). Delivery to Israel of doses of Arcturus’ COVID-19 vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones.

News for Arcturus Therapeutics Stock (ARCT)